Attached files
| file | filename |
|---|---|
| 10-Q - QUARTERLY REPORT - Immune Therapeutics, Inc. | tnib_10q.htm |
| EX-31.2 - CERTIFICATION - Immune Therapeutics, Inc. | tnib_ex312.htm |
| EX-32.1 - CERTIFICATION - Immune Therapeutics, Inc. | tnib_ex321.htm |
| EX-31.1 - CERTIFICATION - Immune Therapeutics, Inc. | tnib_ex311.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Immune Therapeutics, Inc. | Financial_Report.xls |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of TNI BioTech, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2013 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
|
Date: August 12, 2013
|
By:
|
/s/ Peter Aronstam
|
|
| Peter Aronstam | |||
| Chief Financial Officer |